Skip to content
Smart Scholars🛡 Scholar Shield🏛 Research Integrity Desk🧩 Portfolio Console📰 Journals🔧 DOI MembersTools🔎 Journal AuditGI GetIndexedDr DOI Doctor

Cite this DOI

10.46243/jst.2021.v6.i04.pp292-301 · Design and In-vivo Assessment of Quercetin-Based Nanosponges Buccal Quercetin Tablets

APA (7th edition)

Dr.Ratnasree, Dr.Rafia, & Shivaprasad (2021). Design and In-vivo Assessment of Quercetin-Based Nanosponges Buccal Quercetin Tablets. *Journal of Science & Technology*, *06*(04), 292–301. https://doi.org/10.46243/jst.2021.v6.i04.pp292-301

⬇ text Italics are shown as *asterisks* in plain text — the journal or book title and the volume.

BibTeX

@article{drratnasree2021design,
  author    = {Dr.Ratnasree and Dr.Rafia and Shivaprasad},
  title     = {{Design and In-vivo Assessment of Quercetin-Based Nanosponges Buccal Quercetin Tablets}},
  journal   = {Journal of Science \& Technology},
  year      = {2021},
  month     = {jul},
  volume    = {06},
  number    = {04},
  pages     = {292--301},
  publisher = {Longman Publishers},
  issn      = {2456-5660},
  doi       = {10.46243/jst.2021.v6.i04.pp292-301},
  url       = {https://doi.org/10.46243/jst.2021.v6.i04.pp292-301},
  language  = {en},
  abstract  = {The goal was to use cyclodextrin-based nanosponges to create a controlled release formulation that would boost quercetin's bioavailability. Using the freeze-drying method, a 3-factor, 3-level Box-Behnken design containing quercetin was loaded into nanosponges based on the results of preliminary testing. After being manufactured, characterized, and formed into tablets, the prepared nanosponges were inspected. The drug release percentages at six hours range from 53.04 to 82.64\% for the quercetin-loaded nanosponges, whereas the particle sizes range from 36.45 to 135.27 nm and the encapsulation efficiencies from 42.37 to 88.44\%. The Quercetin-nanosponge interaction was confirmed by FTIR, DSC, and XRD analyses. After the nanosponges were converted into tablets, the medication released from them at a rate of 99.75\% in vitro, and stability tests revealed no appreciable alterations six months later. Rats were used in in vivo investigations to compare the Cmax of quercetin optimized nanosponges tablets (6.27 ± 0.06 ng/mL) to the Cmax of the pure medication (3.07 ± 0.086 ng/mL), which was substantially lower (p<0.05). The Tmax values for the pure drug solution and the nanosponges tablet formulation were 0.5 ± 0.08 h and 4.0 ± 0.07 h, respectively.}
}

⬇ .bib

RIS (EndNote, Zotero, Mendeley)

TY  - JOUR
TI  - Design and In-vivo Assessment of Quercetin-Based Nanosponges Buccal Quercetin Tablets
AU  - Dr.Ratnasree
AU  - Dr.Rafia
AU  - Shivaprasad
JO  - Journal of Science & Technology
PY  - 2021
DA  - 2021/07/27/
VL  - 06
IS  - 04
SP  - 292
EP  - 301
PB  - Longman Publishers
SN  - 2456-5660
LA  - en
AB  - The goal was to use cyclodextrin-based nanosponges to create a controlled release formulation that would boost quercetin's bioavailability. Using the freeze-drying method, a 3-factor, 3-level Box-Behnken design containing quercetin was loaded into nanosponges based on the results of preliminary testing. After being manufactured, characterized, and formed into tablets, the prepared nanosponges were inspected. The drug release percentages at six hours range from 53.04 to 82.64% for the quercetin-loaded nanosponges, whereas the particle sizes range from 36.45 to 135.27 nm and the encapsulation efficiencies from 42.37 to 88.44%. The Quercetin-nanosponge interaction was confirmed by FTIR, DSC, and XRD analyses. After the nanosponges were converted into tablets, the medication released from them at a rate of 99.75% in vitro, and stability tests revealed no appreciable alterations six months later. Rats were used in in vivo investigations to compare the Cmax of quercetin optimized nanosponges tablets (6.27 ± 0.06 ng/mL) to the Cmax of the pure medication (3.07 ± 0.086 ng/mL), which was substantially lower (p<0.05). The Tmax values for the pure drug solution and the nanosponges tablet formulation were 0.5 ± 0.08 h and 4.0 ± 0.07 h, respectively.
DO  - 10.46243/jst.2021.v6.i04.pp292-301
UR  - https://doi.org/10.46243/jst.2021.v6.i04.pp292-301
ER  -

⬇ .ris

CSL-JSON

{
    "type": "article-journal",
    "id": "10.46243/jst.2021.v6.i04.pp292-301",
    "DOI": "10.46243/jst.2021.v6.i04.pp292-301",
    "URL": "https://doi.org/10.46243/jst.2021.v6.i04.pp292-301",
    "title": "Design and In-vivo Assessment of Quercetin-Based Nanosponges Buccal Quercetin Tablets",
    "source": "Smart Scholars Registry",
    "container-title": "Journal of Science & Technology",
    "author": [
        {
            "family": "Dr.Ratnasree"
        },
        {
            "family": "Dr.Rafia"
        },
        {
            "family": "Shivaprasad"
        }
    ],
    "issued": {
        "date-parts": [
            [
                2021,
                7,
                27
            ]
        ]
    },
    "volume": "06",
    "issue": "04",
    "page": "292-301",
    "publisher": "Longman Publishers",
    "language": "en",
    "abstract": "The goal was to use cyclodextrin-based nanosponges to create a controlled release formulation that would boost quercetin's bioavailability. Using the freeze-drying method, a 3-factor, 3-level Box-Behnken design containing quercetin was loaded into nanosponges based on the results of preliminary testing. After being manufactured, characterized, and formed into tablets, the prepared nanosponges were inspected. The drug release percentages at six hours range from 53.04 to 82.64% for the quercetin-loaded nanosponges, whereas the particle sizes range from 36.45 to 135.27 nm and the encapsulation efficiencies from 42.37 to 88.44%. The Quercetin-nanosponge interaction was confirmed by FTIR, DSC, and XRD analyses. After the nanosponges were converted into tablets, the medication released from them at a rate of 99.75% in vitro, and stability tests revealed no appreciable alterations six months later. Rats were used in in vivo investigations to compare the Cmax of quercetin optimized nanosponges tablets (6.27 ± 0.06 ng/mL) to the Cmax of the pure medication (3.07 ± 0.086 ng/mL), which was substantially lower (p<0.05). The Tmax values for the pure drug solution and the nanosponges tablet formulation were 0.5 ± 0.08 h and 4.0 ± 0.07 h, respectively.",
    "ISSN": "2456-5660"
}

⬇ .json What citeproc and reference managers read; the DOI system hands it out for Accept: application/vnd.citationstyles.csl+json, and so does this registry's resolver.

From the record as registered (version 2) — the record and its history. Programs: https://registry.smartscholars.in/api.php?action=cite&doi=10.46243%2Fjst.2021.v6.i04.pp292-301 gives all four in one JSON answer.

Share this page

Share this page

Ask AI about this page

Everything Smart Scholars runs

Nine sites, one account. A journal starts at the audit; an author starts at Scholar Shield.

What we do: DOIs registered from what a journal already has · Crossref records completed — references, abstracts, licences, ORCID iDs, affiliations and ROR IDs, funding · DOIs that resolve · articles preserved · journals rated on the public record · see everything we do →

Book a free call

For journals & publishers

Start with the audit — ₹4,999 per journal, and the gate to everything else.

DOI care

Every service on one journal profile — each previews first and acts only on your approval.

  • DOI Doctor — check & repairevery DOI tested at doi.org and Crossref; dead links, abstracts, licences, ORCIDs
  • Smart Deposita new DOI from your PDF, Word file, article page, JATS XML or spreadsheet — every value shown with its source, deposited once you confirm it
  • DOI census (Excel)site against Crossref, both directions, with a copy-paste fix per article
  • Backfile DOIsDOIs for older articles that never had one — no per-DOI fee of ours
  • DOIs for conference proceedingsthe conference, the volume and every paper — registered in the organiser's own name
  • Scopus indexing guidethe minimum criteria, the 14 CSAB criteria and how a title is suggested — from Elsevier's own page
  • Embase indexing guidewhat Embase asks of a biomedical journal and how to suggest it
  • Write DOIs into OJSthe verified DOIs pushed onto your article pages through your own API
  • Silent-failure monitorweekly checks of site, OAI-PMH, Scholar tags, ISSN, preservation, hijack lists
  • Journal Radarevery journal, every day: SSL, DNS, redirects, robots.txt, OJS, DOIs, Crossref metadata, broken links — what broke since yesterday first
  • Verified metrics & badgesa public, dated, source-linked metrics page and a "cited by" badge
  • Quality dossier (PDF)one PDF for universities, authors and reviewers
  • Author citation enginethe citation steps emailed to each author from the journal's own mailbox
  • JATS XMLmachine-readable JATS per article
  • Duplicate articlesthe same paper published twice — you choose which copy stays

For authors & researchers

Free to use. Nothing you check is shared with the journal.

For institutions, sponsors & DOI operators

Smart Scholars

Mon–Sat, 10:00–19:00 IST. The Ask AI button on every page answers about our services at any hour.

News

Policies

What we can register a DOI for

20 kinds of record, one account, one place. Every one gets a DOI that resolves, metadata that indexes read, and a record that stays correct afterwards.

Journals

  • Journal articles
  • Journal titles
  • Pending publications
  • Peer reviews
  • Preprints & posted content

Books & conferences

  • Books
  • Book chapters
  • Book series
  • Book sets
  • Conference proceedings
  • Proceedings series
  • Conference papers

Other research output

  • Theses & dissertations
  • Reports & working papers
  • Report series
  • Standards
  • Databases
  • Datasets
  • Figures, tables & supplements

Funding

  • Grants & funding awards

Elsewhere

The same company, in the places our publishers already read.
Add Smart Scholars as a preferred source on GoogleSee more of our newsroom in Google’s Top Stories.
Smart Scholars · Every service on one pageNewsroom posts CC BY 4.0 · DOI metadata CC0 · everything else ©Data from OpenAlex (openalex.org), CC0 · Crossref · ISSN Portal · DOAJContact
WhatsApp